Read a refresh of breast cancer FDA news from August 2026, including an sNDA application in PIK3CA-mutant disease and a fast track designation.
|Articles|October 7, 2022
Practical Approaches to Treatment in Breast Cancer
In 2 workshops moderated by Mark Pegram, MD, and Joyce A. O'Shaughnessy, MD, oncologists who specialize in the treatment of breast cancer met to discuss best practices for biomarker testing, the emerging concept of HER2-low BC, and treatment approaches for BC throughout the course of the disease. This article summarizes key takeaways and stakeholder insights from these workshops.
Advertisement
Advertisement
Related to this article
Lanreotide injection, a generic formulation referencing lanreotide, was approved by the FDA for GEP-NETs management.
The FDA granted final approval to aLutetium Lu 177 dotatate biosimilar for patients with SSTR-positive GEP-NETs.
The TrueBeam photon therapy system has been added to the Statesir Cancer Center at Atlantic Health CentraState Medical Center.
The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC.
Updated NCCN guidelines now recommend rusfertide as a Category 1 option for both low- and high-risk polycythemia vera.
An observational analysis showed a long-term OS benefit with Orca-T in adult patients undergoing allogeneic transplantation for hematologic malignancies.
FDA has granted fast track designation to LYT-200 plus a hypomethylating agent in relapsed/refractory high-risk myelodysplastic syndromes.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
2
NAPISTAR-1-01 Data Support Rapid TUB-040 Development in Biomarker-Unrestricted Ovarian Cancer
3
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
4
Making Invisible Cancers Visible: Study Suggests a New Route to Turn ‘Cold’ Tumors ‘Hot’
5